



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 629 347 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

(21) Application number: 92924028.1

(51) Int. Cl.5: A01N 63/00, A61K 37/00

(22) Date of filing: 30.11.92

(86) International application number:
PCT/JP92/01563

(87) International publication number:
WO 93/14640 (05.08.93 93/19)

(30) Priority: 23.01.92 JP 32660/92
11.03.92 JP 52943/92
30.09.92 JP 262143/92
30.09.92 JP 262559/92

(43) Date of publication of application:
21.12.94 Bulletin 94/51

(84) Designated Contracting States:
BE CH DE DK FR GB IT LI NL SE

(71) Applicant: MORINAGA MILK INDUSTRY CO., LTD.
33-1, Shiba 5-chome
Minato-ku, Tokyo 108 (JP)

(72) Inventor: TOMITA, Mamoru
1-47-6, Higashi-asahina,
Kanazawa-ku
Yokohama-shi,
Kanagawa 236 (JP)
Inventor: SHIMAMURA, Seiichi
1558, Shinohara-cho,
Kohoku-ku
Yokohama-shi,
Kanagawa 222 (JP)
Inventor: KAWASE, Kozo
761-1, Shirokuwa,
Urawa-shi
Saltama 338 (JP)

Inventor: FUKUWATARI, Yasuo
3-1-4-103, Nijigaoka,
Aso-ku
Kawasaki-shi,
Kanagawa 215 (JP)
Inventor: TAKASE, Mitsunori
138-10, Minami-nakamaru
Omiya-shi,

Saltama 330 (JP)

Inventor: BELLAMY, Wayne Robert
C-5 Vira-Sagamino-West,
3-22-6, Higashihara

Zama-shi,

Kanagawa 228 (JP)

Inventor: YAMAUCHI, Koji 405
Garden-Haltsu-Kamakura-Tamanawa
4-2-2, Tamanawa

Kamakura-shi,

Kanagawa 247 (JP)

Inventor: WAKABAYASHI, Hiroyuki,
Morinaga-Kibogaoka-Ryo

118, Minami-kibogaoka,

Asahi-ku

Yokohama-shi,

Kanagawa241 (JP)

Inventor: TOKITA, Yukiko

201 Flattosuton-Sagami,

3-6, Asahi-cho

Sagamihara-shi,

Kanagawa 228 (JP)

(74) Representative: Holmes, Michael John
Frank B. Dehn & Co.
European Patent Attorneys
Imperial House
15-19 Kingsway
London, WC2B 6UZ, (GB)

(54) ANTIBACTERIAL AGENT AND TREATMENT OF ARTICLE THEREWITH.

(57) An antibacterial agent containing as the active ingredients a compound selected from the group consisting of a decomposition product of lactoferrin, a lactoferrin-related antibacterial peptide and an arbitrary mixture thereof, another specified compound and/or an antibiotic; and a method of treating an article with the agent. This agent has an excellent antibacterial effect on a wide variety of microbes and is utilizable not only as a drug but also for disinfecting various articles such as food and quasi drug safely and efficiently.

TECHNICAL FIELD

5 The present invention relates to antimicrobial agents and method for treating products therewith. More particularly, the present invention relates to new antimicrobial agents having excellent antimicrobial activity against wide variety of microorganisms, and method for safely treating various products, e.g., foods, medicines, and the like with such an agent.

BACKGROUND ART

10 It is known that lactoferrin is a natural iron-binding protein occurring in vivo, e.g. in lacrima, saliva, peripheral blood, milk and the like, and that it exhibits antimicrobial activity against various harmful microorganisms belonging to genera of Escherichia, Candida, Closidium, and the like (Journal of Pediatrics, Vol. 94, Page 1, 1979). It is also known that lactoferrin exhibits antimicrobial activity, in a concentration of 0.5-30 mg/ml, against microorganisms belonging to genera of Staphylococcus and Entrococcus (Non-necke, B.J. and Smith, K.L.: Journal of Dairy Science, Vol. 67, page 606, 1984).

15 On the other hand, a number of inventions are known for peptides having antimicrobial activity against various microorganisms. Some of examples of such peptides are: phosphono-tripeptide (Japanese Unexamined Patent Application Gazette No. 57(1982)-106689), phosphono dipeptide derivatives (Japanese Unexamined Patent Application Gazette No. 58(1983)-13594), and cyclic peptide derivatives (Japanese Unexamined Patent Application Gazette No. 58(1983) 213744) which are effective against Gram positive and Gram negative bacteria; peptides having antimicrobial and antiviral activities (Japanese Unexamined Patent Application Gazette No. 59(1984)-51247); polypeptides effective against yeast (Japanese Unexamined Patent Application Gazette No. 60(1985)-130599); glycopeptides derivatives effective against Gram positive bacteria (Japanese Unexamined Patent Application Gazette Nos. 60(1985)-172998, 61(1986)-251699, 63- (1988)-44598); oligopeptides effective against Gram positive bacteria (Japanese Unexamined Patent Application Gazette No. 62(1987)-22798); peptide antibiotics (Japanese Unexamined Patent Application Gazette Nos. 62(1987)-51697, 63(1988)-17897); antimicrobial peptides extracted from blood cells of Tachyplesus tridentatus from North America (Japanese Unexamined Patent Application Gazette No. Heisei 2-(1990)-53799); antimicrobial peptides isolated from hemolymph of bees (Japanese Unexamined Patent Application (via PCT root) Gazette No. Heisei 2(1990)-500084), and the like.

20 The inventors of this invention contemplated to isolate useful substances, which do not have undesirable side effects (e.g. antigenicity) and which have heat-resistance as well as potent antimicrobial activity, from nature at a reasonable cost, and found the fact that hydrolysates of lactoferrin obtainable by acid or enzyme hydrolysis of mammalian lactoferrin, apo-lactoferrin, and/or metal chelated lactoferrin (hereinafter they are referred to as lactoferrins) have more potent heat-resistance and antimicrobial activity than unhydrolyzed lactoferrins, for which a patent application has been filed (Japanese Patent Application No. Heisei 3(1991)-171736).

25 Furthermore, the inventors of this invention previously found a number of peptides, originated from the lactoferrins, which do not have side effects (e.g. antigenicity), and which have heat-resistance as well as a potent antimicrobial activity, e.g. antimicrobial peptides having 20 amino acid residues (Japanese Patent Application No. Heisei 3(1991) 186260), antimicrobial peptides having 11 amino acid residues (Japanese Patent Application No. Heisei 3(1991) 48196), antimicrobial peptides having 6 amino acid residues (Japanese Patent Application No. Heisei 3(1991)-94492), antimicrobial peptides having 5 amino acid residues (Japanese Patent Application No. Heisei 39(1991)-94493), and antimicrobial peptides having 3-6 amino acid residues (Japanese Patent Application No. Heisei 3(1991)-94494), for which patent applications have been filed.

30 Heretofore, various studies have been made to potentiate the antimicrobial activity of lactoferrin, and IgA and glycopeptides are known as the auxiliary agents for potentiating such a physiological activity. There are many reports in this respect, for example, a method for potentiation of the antimicrobial activity of lactoferrin by coexistence of lysozyme therewith (Japanese Unexamined Patent Application Gazette No. 62- (1987)-249931), a method for potentiation of antimicrobial activity of lactoferrin by coexistence of secretory IgA therewith (Stephens, S. et al.: Immunology; Vol. 41, Page 597, 1980) and so on. Furthermore, Spick et al. report that lactoferrin has an activity to inhibit bacteria from adhering onto mucous membrane, and that this activity is potentiated by coexistence of lysozyme or glycopeptides (Edit. by William, A.F. and Baum, J.D.: "Human Milk Banking", Nestle Nutrition Workshop Series, Vol. 5, Page 133, Pub. by Raven Press Books, Ltd.).

35 The efficacy of combined use of lactoferrin and antibiotics has been also studied, and cephem antibiotics (Miyazaki, S. et al.: Chemotherapy, Vol. 39, Page 829, 1991), β lactum antibiotics (Japanese

Unexamined Patent Application Gazette No. Heisei 1-319463), and the like are known as the antibiotics which may potentiate antimicrobial activity upon the combined use with lactoferrin.

However, there have been no study about the efficacy of combined use of lactoferrin hydrolysate or antimicrobial peptides derived from lactoferrins and specific compounds and/or antibiotics, consequently 5 there have been no antimicrobial agents containing such substances as their effective ingredients. Furthermore, there has been no attempt to treat various matters such as foods, medicines and the like with such an agent.

DISCLOSURE OF INVENTION

10 The present invention is made under the aforementioned background. Therefore, it is an object of the present invention to provide antimicrobial agents which have potentiated antimicrobial activity by combined use of lactoferrin hydrolysate and/or lactoferrin-derived antimicrobial peptides, which are previously invented by the inventors, and specific compounds and/or antibiotics.

15 In order to realize the object, this invention provides antimicrobial agents which include as the effective ingredients: (A) lactoferrin hydrolysate, one or more of antimicrobial peptides derived from lactoferrins; and (B) one or more compounds selected from the group consisting of metal-chelating protein, tocopherol, cyclodextrin, glycerin fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, and cholic acid.

20 This invention also provides: antimicrobial agents which include, as the effective ingredients, (A) lactoferrin hydrolysate, one or more of antimicrobial peptides derived from lactoferrins, and (C) an antibiotic; and antimicrobial agents which include, as the effective ingredients, (A) one or more of antimicrobial peptides derived from lactoferrins, (C) an antibiotic, and (B) one or more compounds selected from the group consisting of metal-chelating protein, lysozyme, decomposed casein, tocopherol, cyclodextrin, glycerin-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, and cholic acid.

25 Furthermore, this invention also provides a method for treating products with either one of said antimicrobial agents.

30 BEST MODE FOR CARRYING OUT THE INVENTION

In the present invention, the term "lactoferrins" includes: lactoferrin on the market; lactoferrin isolated from mammalian (humans, cows, sheep, goats, horses and the like) milk such as colostrum, transitional milk, matured milk, milk in later lactation, and the like or processed products thereof such as skim milk and 35 whey by any conventional method (e.g. ion-exchange chromatography); apo lactoferrin obtainable by de-ironization of lactoferrin with hydrochloric acid, citric acid, and the like; metal-saturated or partially metal-saturated lactoferrin obtainable by chelation of apo-lactoferrin with a metal such as iron, copper, zinc, manganese, and the like. Lactoferrins purchased in the market or prepared in accordance with any known method can be used for preparation of the antimicrobial peptides.

40 The lactoferrin hydrolysate used in the present invention can be obtained by hydrolysing the above-mentioned lactoferrins with acid or enzyme, and for example, can be obtained by a method described in the specification of Japanese Patent Application No. 171736/91. In case in which lactoferrin hydrolysate is obtained using an acid, the lactoferrin is dissolved in water, after which an inorganic acid or an organic acid is added to the solution, and is hydrolyzed by heating the solution at a given temperature and for a duration.

45 In the case in which the lactoferrin hydrolysate is obtained using an enzyme, the lactoferrin is hydrolyzed by adjusting the pH of the lactoferrin solution approximately to the optimal pH of the enzyme used, adding an enzyme such as pepsin or trypsin and maintaining the solution at a given temperature for a duration, and then the enzyme is inactivated by a conventional method, the hydrolysate obtained by hydrolysis using acid or enzyme is a mixture of antimicrobial peptide having various molecular weight. A degree of decomposition 50 by the above-mentioned hydrolysis is desirably 6-20%, for which the degree is calculated with the following formula in which the total nitrogen of sample was measured by Kjeldahl method and formol nitrogen was measured by Folin titration method:

$$\text{Decomposition degree} = (\text{Formol nitrogen} / \text{Total nitrogen}) \times 100.$$

55 In the below description, value of percentage except for the decomposition degree is by weight.
The reaction liquid (i.e., solution of lactoferrin hydrolysate) obtained by the hydrolysis using an acid or an enzyme is cooled by conventional methods and neutralized, desalinated or decolorized, as needed.

Furthermore, the solution is fractionated by conventional methods, as needed, and then thus obtained hydrolysate is mixed with a specific compound and/or antibiotic in a form of a solution so obtained, a concentrated liquid, or a dried powder.

In the present invention, the term "antimicrobial peptides derived from lactoferrins" includes: antimicrobial peptides obtainable by isolation from the decomposition product (hydrolysate) of lactoferrins; antimicrobial peptides having chemical structures (amino acid sequences) which are the same or homologous to those of said antimicrobial peptide obtained from said decomposition products of lactoferrins; antimicrobial peptide derivatives having chemical structures (amino acid sequences) which are the same or homologous to those of said antimicrobial peptides obtained from said decomposition products of lactoferrins; and a mixture comprising any of the foregoing antimicrobial peptides or derivatives thereof.

These antimicrobial peptides derived from lactoferrins are obtainable by the methods disclosed in Japanese Patent Applications Nos. Heisei 3(1991)-186260, Heisei 3(1991)-48198, Heisei 3(1991)-94492, Heisei 3(1991) 94493, and Heisei 3(1991)-94494. For example, antimicrobial peptides can be obtained; by a method wherein lactoferrins are subjected to acid hydrolysis or enzymatic hydrolysis, then fractions containing antimicrobial peptides are collected from the resultant peptides mixture by suitable separation means such as liquid phase chromatography and the like; by a method wherein the amino acids sequences of the antimicrobial peptides obtained in the manner as mentioned above are determined by a known method (e.g. vapor phase sequencer), then synthesize the peptides by a known method (e.g. peptide synthesizer); or by any other known methods. These antimicrobial peptides derived from lactoferrins include: antimicrobial peptides having following amino acid sequences of Sequence Nos. 1, 2, and 27 or derivatives thereof (Japanese Patent Application No. Heisei 3(1991)-48196); antimicrobial peptides of Sequence Nos. 3, 4, 5, and 6 or derivatives thereof (Japanese Patent Application No. Heisei 3(1991)-94492); antimicrobial peptides of Sequence Nos. 7, 8, 9, and 31 or derivatives thereof (Japanese Patent Application No. Heisei 3(1991)-94493); antimicrobial peptides of Sequence Nos. 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 21 or derivatives thereof (Japanese Patent Application No. Heisei 3(1991)-94494); and antimicrobial peptides of Sequence Nos. 22, 23, 24, 25, 26, 28, 29, and 30 or derivatives thereof (Japanese Patent Application No. Heisei 3(1991)-186260).

These antimicrobial peptides can be mixed as it is, or in a form of solution, concentrated liquid, or dried powder with one or more compounds and/or one or more antibiotics specified hereunder.

The specific compounds which can be mixed with said lactoferrin hydrolysate and/or said antimicrobial peptides derived from lactoferrins are: metal chelating protein, tocopherol, cyclodextrin, glycerin-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, cholic acid, and a mixture of two or more of the compounds enumerated above. The specific compounds enumerated can be purchased in the market, or alternatively can be prepared by any known methods.

The metal-chelating proteins include proteins which may produce a chelate compounds by coordination with metal ions, and some of which can be enumerated, for example, lactoferrin, transferrin, conalbumin, casein phosphopeptides, and the like.

α -cyclodextrin, β -cyclodextrin, γ -cyclodextrin, δ -cyclodextrin, and alkyl-derivatives thereof (branching cyclodextrin) can be enumerated as the examples of cyclodextrin.

The glycerin-fatty acid ester and derivatives thereof include ester made from fatty acid, and glycerin and/or polyglycerin.

The alcohol include mono-, di-, tri-, and poly-aliphatic alcohol, for example, ethanol, propylene glycol, glycerol and the like can be enumerated.

It can be properly selected which of lactoferrin hydrolysate and/or antimicrobial peptides and which of the specific compounds (metal-chelating protein, tocopherol, cyclodextrin, glycerin-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, cholic acid, or a mixture of two or more compounds enumerated above) should be assayed in an agent, paying consideration to the use of the agent. A ratio for assayment of ingredients in an antimicrobial agent is properly determined, paying consideration to the kinds of ingredients selected and the use of the agent. In assayment, each of the ingredients can be mixed in a liquid or powder form, where any known diluents and/or excipients can be admixed as occasion demands.

Antibiotics which can be mixed with the lactoferrin hydrolysate and/or the antimicrobial peptides in another embodiment of this invention include penicillin, semisynthetic penicillin, cephem antibiotic, carbapenem antibiotics, monobactam antibiotics, aminoglycoside antibiotics, peptide antibiotics, tetracycline antibiotics, chloramphenicol, macrolide antibiotics, rifampicin, vancomycin, fosfomycin, chemically synthesized antimicrobial agent, antituberculosis drug, and polymyxin B. These antibiotics can be purchased in the market, or alternatively can be prepared in accordance with any known methods.

In a further embodiment of the antimicrobial agent in this invention, specific compounds can be added to the mixture of the antimicrobial peptides and one or more antibiotics, and they are metal-chelating protein, lysozyme, decomposed casein, tocopherol, cyclodextrin, glycerin-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, cholic acid, and a mixture or two or more compounds enumerated above. The compounds referred immediately above are completely the same to those used in the aforementioned embodiment except that lysozyme and decomposed casein are further included. Lysozyme and decomposed casein can be purchased in the market or can be prepared in accordance with any known method. Decomposed casein, for example, is a mixture of decomposed elements of casein derived from bovine milk which are hydrolysed by protease or alkaline, or a specifically fractionated elements of the decomposed casein. In particularly, a mixture of peptides (and amino acid) having average molecular weight of about 380 ranging at least 75 to less than 1000 is desirable.

It can be properly selected: which of lactoferrin hydrolysate and/or antimicrobial peptides derived from lactoferrins and which of antibiotics are to be assorted in an agent; and which of the optional mixtures of the antimicrobial peptides and the antibiotics and which of the specific compounds (metal-chelating protein, lysozyme, decomposed casein, tocopherol, cyclodextrin, glycerin-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, cholic acid, and a mixture of two or more of compounds selected therefrom) are to be mixed in an agent, paying consideration to the use of the agent. A ratio for assortment of ingredients in an antimicrobial agent is properly selected, paying consideration to the kinds of selected ingredients and the use of the agent. In assortment, each of the ingredients can be mixed in a form of liquid or powder, where any known diluents and/or excipients can be admixed as the occasion demands.

The antimicrobial agents in accordance with this invention exhibit potent antimicrobial activity against bacteria, yeast, and fungi, thus they can be used not only as medicines or drugs, but also as additives for any products such as foods and non-medical products which are taken into the bodies of humans or other animals, or which are applied onto or contacted with the body surface of humans or other animals, and for any otherproducts which are generally desired to be prevented or inhibited from proliferation of microorganisms therein. Moreover, the antimicrobial agents of this invention can be used for treatment of any products or materials therefor. More particularly, the antimicrobial agents of this invention can be used in such a manner that: it is orally administered as it is to humans or other animals; it is added to, assorted to, sprayed to, adhered to, coated onto or impregnated into any products such as drugs (e.g. eye lotion, anti-mammitis drug, anti-diarrheals, epidermic agent against athlete's foot, and the like), non-medical pharmaceutical products (e.g. mouth-washing products, sweat suppressant, hair tonic, and the like), cosmetics (e.g. hair liquid, creams, emulsions, and the like), dentifrices (e.g. tooth paste, tooth brushes, and the like), various feminine hygienic products, various products for babies (e.g. diaper, and the like), various geriatric products (e.g. denture cement, diaper, and the like), various detergents (e.g. toilet soaps, medicinal soaps, shampoo, rinse, laundry detergents, kitchen detergents, house detergents, and the like), various sterilized products (e.g. disinfectant-impregnated paper for kitchen, disinfectant-impregnated paper for toilet, and the like), feedstuff (e.g. feed for domestic animals and pets, and the like), materials therefor, as well as any other products which are desired to be sterilized or prevented from microbial pollution. The antimicrobial agents can be used for treatment of any matters which are generally desired to be prevented or inhibited from proliferation of microorganisms.

As will be apparent from the tests described hereinafter, it is worthy of special mention that the antimicrobial agents of this invention exhibit remarkable antimicrobial activity against microorganisms, which are resistant to most of antibiotics, thus single use of the antibiotic is not effective and which causes the problem of Hospital Infection, for example, Methicilin-resistant *Staphylococcus aureus*.

Now, the present invention will be explained in further detail by way of some exemplifying tests.

(I) TESTS FOR ANTIMICROBIAL AGENTS CONTAINING LACTOFERRIN HYDROLYSATE AND/OR ANTIMICROBIAL PEPTIDES DERIVED FROM LACTOFERRIN, AND SPECIFIED COMPOUNDS AS THE EFFECTIVE INGREDIENTS THEREOF

Firstly, preparation of samples and methods which are commonly used in the following tests will be described.

1. Preparation of Samples

(1) Lactoferrin Hydrolysate (Powder)

① Lactoferrin Hydrolysate 1 prepared in accordance with the method stated in Example 1 (infra) was used.

② Lactoferrin hydrolysate 2 prepared in accordance with the method stated in Example 2 (infra) was used.

(2) Antimicrobial Peptide (Powder)

① The peptide (Sequence Number 26) prepared in accordance with the method stated in Example 3 (infra) was used.

② The peptide (Sequence Number 27) prepared in accordance with the method stated in Example 4 (infra) was used.

(3) Lactoferrin: Bovine lactoferrin on the market (by Sigma Company) was used.

(4) Caseinphosphopeptide: Caseinphosphopeptide prepared in accordance with the known method (the method referred in Japanese Unexamined Patent Application Gazette No. 59-159792) was used.

(5) Tocopherol: A commercial product (by Wakoh Junyaku Kohgyoh Company) was used.

(6) β -Cyclodextrin: A commercial product (Nippon Shokuhin Kakoh Company) was used.

(7) 1-Monocapryloyl-rac-Glycerol: A commercial product (by Sigma Company) was used.

(8) Ethyl Alcohol: 99.5% ethyl alcohol on the market (by Nakaraitesk Company) was used.

20 (9) Glycerol: A commercial product (by Nakaraitesk Company) was used.

(10) Propylene Glycol: A commercial product (by Wakoh Junyaku Kohgyoh Company) was used.

(11) EDTA • Na₂: A commercial product (by Wakoh Junyaku Kohgyoh Company) was used.

(12) Ascorbic Acid: A commercial product (by Kantoh Kagaku Company) was used.

(13) Citric Acid: A commercial product (by Nakaraitesk Company) was used.

25 (14) Polyphosphoric Acid: A commercial product (by Merck Company) was used.

(15) Chitosan: A commercial product (by Nakaraitesk Company) was used. The product was dissolved in a weak solution of acetic acid.

(16) L-Cysteine: A commercial product (by Sigma Company) was used. Aqueous solution or the product was sterilized by filtration.

30 (17) Polyethylene Glycol #2000: A commercial product (by Nakaraitesk Company) was used.

(18) Glycerin-Fatty Acid Ester:

① 1-monolauryl-rac-glycerol: A commercial product (by Sigma Company) was used.

② 1-monomyristoyl-rac-Glycerol: A commercial product (by Sigma Company) was used.

③ 1-monostearoyl-rac-glycerol: A commercial product (by Sigma Company) was used.

35 Either one was used in a form of an aqueous suspension.

(19) Cholic Acid: A commercial product (by Wakoh Junyaku Kohgyoh Company) was used in an aqueous suspension.

2. Method

40

(1) Preparation of Preculture of Staphylococcus:

From the preservation slant of *Staphylococcus aurcus* (JCM-2151), a loop of the bacterial strain was taken out and spread onto standard agar culture medium (by Eiken Kagaku Company) then cultivated for 16 hours at 37°C. The colonies grown on the culture medium were scraped by a platinum loop and cultivated in 1% peptone (by Difco Company) culture medium for several hours at 37°C, and the resultant microbial culture at logarithmic phase was used as the preculture in a serial concentration of 3 × 10⁸/ml.

(2) Preparation of Basal Medium (Cow's Milk Medium):

50

A quantity of commercial cow's milk was diluted 2-fold with distilled water, the resultant liquid was sterilized at 115°C for 15 minutes, to thereby obtain the basal medium.

(3) Preparation of Test and Control Media:

(3-1) Preparation of Test Media

5 Aqueous solutions of the samples of lactoferrin hydrolysates (sample (1), in Preparation of Samples, supra), the samples of antimicrobial peptides (sample (2), supra), and the samples of compounds (3), (4), (6), (11), (12), (13), and (16) (in Preparation of Samples, supra) were respectively dealt with sterilization filters (by Advantec Company). A quantity of the resultant solutions of the samples were selectively mixed with a quantity of the basal medium, thereby test media for the respective tests were prepared in the
 10 combinations and eventual concentrations as specified in the respective tests.

Utilizing the samples (5), (7), (8), (9), (10), (14), (15), (17), (18) and (19), test media were prepared in the same manner as in the preparation of the test media containing sample (3) and the like, except that the aqueous solution (in the cases of samples (5) and (7), aqueous suspensions) were not dealt with sterilization filters.

15 (3-2) Preparation of Control Medium 1

A quantity of commercial cow's milk was diluted 2-fold with distilled water, the resultant liquid was sterilized at 115°C for 15 minutes, thereby control medium 1 was obtained.

20 (3-3) Preparation of Control Media 2

25 Aqueous solutions of the samples of the compounds (3), (4), (6), (11), (12), (13), and (16) referred in Preparation of Samples were respectively sterilized with filters (by Advantec Company), a quantity of the resultant solutions of the samples were selectively mixed with a quantity of the basal medium so that control media 2 were prepared in the combination of samples and in the concentrations corresponding to those in the test media.

30 Utilizing the samples of the compounds (5), (7), (8), (9), (10), (14), (15), (17), (18) and (19) (in Preparation of Samples, supra), control media 2 were prepared in the same manner as in the preparation of the control control media 1 containing samples (3) and the like, except that aqueous solutions (in the cases of the samples (5) and (7), aqueous suspensions) were not sterilized with filters.

(4) Viability Assay

35 To 2ml aliquots of test media prepared in (3-1) (supra), 20ml aliquots of the preculture of *Staphylococcus aureus* prepared in (1) (2. Method, supra) were added, then incubated at 37°C for 1 hour, 200 µl aliquots of the resultant cultures were taken out and diluted with 1% peptone solution in a series of 10ⁿ respectively, 110 µl aliquots of the resultant dilution series were spread onto plates of standard agar culture medium, and after incubation at 37°C for 24 hours the number of colonies grown on the plates were
 40 counted (Test Colony Count).

Control colony counts 1 were determined in the same manner as in the determination of the test colony counts, except that 20ml aliquots of the preculture of *Staphylococcus aureus* prepared in (1) (2. Method, supra) were added to 2ml aliquots of the respective control media 1 prepared in (3-2) (supra). Furthermore, control colony counts 2 were determined in the same manner as in the determination of the
 45 test colony counts, except that 20ml aliquots of the preculture of *Staphylococcus aureus* prepared in (1) (supra) were added to 2ml aliquots of the respective control media 1 prepared in (3-2) (supra).

Survival rates were calculated in accordance with the following formula.

Survival rate 1 - (Test Colony Count/Control Colony Count 1) × 100

50 Survival rate 2 = (Control Colony Count 2/Test Colony Count 1) × 100

(Note: In the tables shown hereinafter, values of survival rate 2 are indicated in the row where the concentration of antimicrobial peptide or lactoferrin hydrolysate is 0.)

55 Test 1

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide (Sequence No. 26, infra) of (2)-① in Preparation of Samples (supra) were adjusted to 0mg, 0.5mg, 1mg,

and 2mg pre ml, and those of the lactoferrin of (3) were adjusted to 0mg, 0.1mg, 1mg, and 10mg per ml respectively.

The results are shown in Table 1. As will be apparent from Table 1, it is confirmed that the coexistence of lactoferrin augments the antimicrobial activity of the peptide. On the other hand, in the case wherein antimicrobial peptide was not added, but lactoferrin was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the lactoferrin. In addition, similar assays were made with respect to antimicrobial peptides other than that specified above and lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of lactoferrin.

10

Table 1

concentration of lactoferrin (mg/ml)	survival rate			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	83	15	3.5
0.1	150	60	7.1	2.2
1	150	43	5.0	1.8
10	104	8.3	0.3	0.1

Test 2

25

Viability assay has made in such a manner that the eventual concentrations in serial dilution of the antimicrobial peptide of (2)-① in Preparation of Samples (supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg per ml, and those of the caseinphosphopeptide of (4) were adjusted to 0mg, 1mg, 10mg, and 20mg per ml respectively.

30

The results are shown in Table 2. As will be apparent from Table 2, it is confirmed that the presence of caseinphosphopeptide augments the antimicrobial activity of the peptide. On the other hand, in the case wherein antimicrobial peptide was not added, but caseinphosphopeptide was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the caseinphosphopeptide. In addition, similar assays were made utilizing antimicrobial peptides other than that specified above and lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of caseinphosphopeptide.

40

Table 2

concentration of caseinphosphopeptide (mg/ml)	survival rate			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	69	15	4.6
1	132	34	3.5	1.4
10	129	14	1.9	0.5
20	150	10	0.7	0.2

Test 3

55

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide of (2)-① in Preparation of Samples (supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg pre ml, and those of the tocopherol of (5) (supra) were adjusted to 0mg, 0.1mg, 0.5mg, and 1mg per ml respectively.

The results are shown in Table 3. As will be apparent from Table 3, it is confirmed that the presence of tocopherol augments the antimicrobial activity of the peptide. On the other hand, in the case wherein antimicrobial peptide was not added, but tocopherol was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the tocopherol. In addition, similar assays were made utilizing antimicrobial peptides other than that specified above and lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of the tocopherol.

Table 3

10

15

20

concentration of tocopherol (mg/ml)	survival rate			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	77	35	12
0.1	101	33	15	5.2
0.5	113	14	6.3	2.4
1	112	7.9	3.5	0.9

Test 4

25

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide of (2)-① in Preparation of Samples (supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg pre ml, and those of the β -cyclodextrin of (6) were adjusted to 0mg, 0.1mg, 1mg, and 2.5mg per ml respectively.

30

The results are shown in Table 4. As will be apparent from Table 4, it is confirmed that the presence of the β -cyclodextrin augments the antimicrobial activity of the peptide. On the other hand, in the case wherein the antimicrobial peptide was not added, but the β -cyclodextrin was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the β -cyclodextrin. In addition, similar assays were made with respect to antimicrobial peptides other than that specified above and lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of the β -cyclodextrin.

35

Table 4

40

45

50

concentration of β -cyclodextrin (mg/ml)	survival rate			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	45	17	8.9
0.1	100	38	22	6.4
1	109	11	3.6	1.4
2.5	88	2.5	1.1	0.2

Test 5

55

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide of (2)-① in Preparation of Samples (supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg pre ml, and those of the monocapryloyl-glycerol of (7) were adjusted to 0mg, 0.5mg, 1mg, and 2mg per ml respectively.

The results are shown in Table 5. As will be apparent from Table 5, it is confirmed that the coexistence of monocapryloyl-glycerol augments the antimicrobial activity of the peptide. On the other hand, in the case

wherein said antimicrobial peptide were not added, but monocapryloyl-glycerol was added, no antimicrobial activity was observed. It is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to the coexistence of the antimicrobial peptide and the monocapryloyl-glycerol, since the potentiation of the antimicrobial activity was far stronger in the case wherein the antimicrobial peptide coexisted with 2 mg/ml of the monocapryloyl-glycerol than in the cases wherein monocapryloyl-glycerol (2mg/ml) alone or antimicrobial peptide (in all concentrations in the serial dilution) alone was included. In addition, similar assays were made utilizing antimicrobial peptides other than that specified above and lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of monocapryloyl-glycerol.

10

Table 5

15	concentration of monocapryloyl-glycerol (mg/ml)	survival rate			
		concentration of antimicrobial peptide (mg/ml)			
		0	0.5	1	2
20	0	100	79	38	9.5
	0.5	103	81	40	7.3
	1	115	18	6.0	1.5
	2	35	0.1	0.03	0.01

25 Test 6

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide of (2)-① in Preparation of Samples (supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg pre ml, and those of the ethyl alcohol of (8) (supra) were adjusted to 0mg, 1mg, 10mg, and 20mg per ml respectively.

30 The results are shown in Table 6. As will be apparent from Table 6, it is confirmed that the ethyl alcohol in a low concentration potentiates the antimicrobial activity of the peptide. On the other hand, in the case wherein the antimicrobial peptide was not added, but the ethyl alcohol was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the ethyl alcohol. In addition, similar assays 35 were made utilizing antimicrobial peptides other than that specified above and lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of the ethyl alcohol.

Table 6

40	concentration of ethyl alcohol (mg/ml)	survival rate			
		concentration of antimicrobial peptide (mg/ml)			
		0	0.5	1	2
45	0	100	72	5.9	1.9
	1	159	50	0.2	0.5
	10	118	20	0.7	0.2
50	20	155	11	0.9	0.1

Test 7

55 Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide of (2)-① in Preparation of Samples (supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg pre ml, and those of the glycerol of (9) were adjusted to 0mg, 1mg, 10mg, and 20mg per ml respectively.

The results are shown in Table 7. As will be apparent from Table 7, it is confirmed that the coexistence of glycerol augments the antimicrobial activity of the peptide. On the other hand, in the case wherein the antimicrobial peptide was not added, but the glycerol was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to 5 coexistence of the antimicrobial peptide and the glycerol. In addition, similar assays were made utilizing antimicrobial peptides other than that specified above and lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of glycerol.

Table 7

concentration of glycerol (mg/ml)	survival rate			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	85	35	7.2
1	100	9.1	1.6	0.7
10	116	4.5	2.5	0.9
20	123	5.2	1.7	1.1

Test 8

25 Viability assay was made with adjusting the eventual concentration of antimicrobial peptide of (2)-① in Preparation of Samples (supra) to 0mg, 0.5mg, 1mg, and 2mg per ml, and those of the propylene glycol of (10) to 0mg, 1mg, 10mg, and 20mg per ml respectively.

30 The results are shown in Table 8. As will be apparent from Table 8, it is confirmed that propylene glycol augmented the antimicrobial activity of the peptide. On the other hand, in the case wherein the antimicrobial peptide was not added, but the propylene glycol was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to 35 coexistence of the antimicrobial peptide and the propylene glycol. In addition, similar assays were made utilizing antimicrobial peptides other than that specified above and lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of propylene glycol.

Table 8

concentration of propylene glycol (mg/ml)	survival rate			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	61	35	20
1	82	23	5.5	3.2
10	118	9.8	7.5	1.5
20	118	5.6	5.2	1.8

50 Test 9

Viability assay was made in such a manner that the eventual concentrations of the lactoferrin hydrolysate 1 of (1)-① in Preparation of Samples (supra) were adjusted to 0mg, 10mg, 20mg, and 40mg 55 per ml, and those of the EDTA • Na₂ of (11) were adjusted to 0mg, 0.1mg, 1mg and 5mg per ml respectively.

The results are shown in Table 9. As will be apparent from Table 9, it is confirmed that the EDTA • Na₂ augments the antimicrobial activity of the lactoferrin hydrolysate. On the other hand, In the case wherein the

lactoferrin hydrolysate 1 was not added, but the EDTA • Na₂ was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the lactoferrin hydrolysate 1 and the EDTA • Na₂. In addition, similar essays were made substituting lactoferrin hydrolysate 1 with antimicrobial peptides, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of EDTA • Na₂.

Table 9

concentration of EDTA • Na ₂ (mg/ml)	survival rate			
	concentration of lactoferrin hydrolysate (mg/ml)			
	0	10	20	40
0	100	90	11	3.7
0.1	122	48	5.2	1.8
1	115	19	0.4	0.3
5	101	4.5	0.2	0.1

20

Test 10

Viability assay was made in such a manner that the eventual concentrations of the lactoferrin hydrolysate 1 (1) ① in Preparation of Samples (supra) were adjusted to 0mg, 10mg, 20mg, and 40mg per ml, and those of the ascorbic acid of (12) were adjusted to 0mg, 0.1mg, 0.5mg and 1mg per ml respectively.

The results are shown in Table 10. As will be apparent from Table 10, it is confirmed that ascorbic acid augments the antimicrobial activity of the lactoferrin hydrolysate 1. On the other hand, in the case wherein the lactoferrin hydrolysate 1 was not added, but the ascorbic acid was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of the antimicrobial activity is resulted from potentiation due to coexistence of the lactoferrin hydrolysate 1 and the ascorbic acid. In addition, similar essays were made substituting the lactoferrin hydrolysate 1 with antimicrobial peptides, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of ascorbic acid.

35

Table 10

concentration of ascorbic acid (mg/ml)	survival rate			
	concentration of lactoferrin hydrolysate (mg/ml)			
	0	10	20	40
0	100	85	12	5.5
0.1	122	41	11	2.6
0.5	115	15	2.5	0.8
1	132	17	0.8	0.2

50 Test 11

Viability assay was made in such a manner that the eventual concentrations of the lactoferrin hydrolysate 1 of (1)-① in Preparation of Samples (supra) were adjusted to 0mg, 10mg, 20mg, and 40mg per ml, and those of the citric acid of (13) (supra) were adjusted to 0mg, 0.1mg, 1mg and 5mg per ml respectively.

The results are shown in Table 11. As will be apparent from Table 11, it is confirmed that the citric acid augments the antimicrobial activity of the lactoferrin hydrolysate 1. On the other hand, in the case wherein the lactoferrin hydrolysate 1 was not added, but the ascorbic acid was added, no antimicrobial activity was

observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the lactoferrin hydrolysate 1 and the citric acid. In addition, similar assays were made substituting the lactoferrin hydrolysate 1 with antimicrobial peptides, thereby it is confirmed that the antimicrobial activity was potentiated by the coexistence of citric acid.

5

Table 11

concentration of citric acid (mg/ml)	survival rate			
	concentration of lactoferrin hydrolysate (mg/ml)			
	0	10	20	40
0	100	75	6.2	2.0
0.1	148	41	2.8	3.4
1	140	28	1.9	1.1
5	130	16	0.8	0.5

20 Test 12

Viability assay was made in such a manner that the eventual concentrations of the lactoferrin hydrolysate 1 of (1)-① in Preparation of Samples (supra) were adjusted to 0mg, 10mg, 20mg, and 40mg per ml, and those of the polyphosphoric acid of (14) were adjusted to 0mg, 0.1mg, 1mg and 5mg per ml respectively.

The results are shown in Table 12. As will be apparent from Table 12, it is confirmed that the presence of polyphosphoric acid augments the antimicrobial activity of the lactoferrin hydrolysate 1. On the other hand, in case wherein the lactoferrin hydrolysate 1 was not added, but the polyphosphoric acid was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the lactoferrin hydrolysate 1 and the polyphosphoric acid. In addition, similar assays were made substituting the lactoferrin hydrolysate 1 with antimicrobial peptides, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of polyphosphoric acid.

35

Table 12

concentration of polyphosphoric acid (mg/ml)	survival rate			
	concentration of lactoferrin hydrolysate (mg/ml)			
	0	10	20	40
0	100	74	8.2	2.2
0.1	140	20	1.1	0.9
1	124	15	0.3	1.3
5	111	3.5	0.4	0.3

50 Test 13

Viability assay was made in such a manner that the eventual concentrations in serial dilution of the antimicrobial peptide (Sequence No. 27) of (2)-② in Preparation of Samples (supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg per ml, and those of the chitosan of (15) were adjusted to 0mg, 0.004mg, 0.02mg and 0.1mg per ml respectively.

The results are shown in Table 13. As will be apparent from Table 13, it is confirmed that the presence of the ascorbic acid augments the antimicrobial activity of the peptide. On the other hand, in the case wherein the antimicrobial peptide was not added, but chitosan was added, antimicrobial activity was low.

Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the chitosan. In addition, similar assays were made substituting the antimicrobial peptide with lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of chitosan.

5

Table 13

10

concentration of chitosan (mg/ml)	survival rate			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	100	85	21
0.004	108	94	8.5	2.2
0.02	71	41	2.1	0.4
0.1	5.2	1.4	0.2	0.05

15

Test 14

20

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide of (2)-② in Preparation of samples (supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg per ml, and those of the L-cysteine of (16) were adjusted to 0mg, 1mg, 5mg and 10mg per ml respectively.

25

The results are shown in Table 14. As will be apparent from Table 14, it is confirmed that the presence of the L-cysteine augments the antimicrobial activity of the peptide. On the other hand, in the case wherein the antimicrobial peptide was not added, but the L-cysteine was added, antimicrobial activity was low. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the L-cysteine. In addition, similar assays were made substituting the antimicrobial peptide with lactoferrin hydrolysates, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of the L-cysteine.

30

Table 14

35

45

concentration of L-cysteine (mg/ml)	survival rate			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	78	25	15
1	37	12	2.3	0.7
5	4.5	2.1	0.09	0.03
10	0.3	0.06	0.02	<0.004

Test 15

Viability assay was made in such a manner that the eventual concentrations of the lactoferrin hydrolysate 2 of (1)-② in Preparation of Samples (supra) were adjusted to 0mg, 10mg, 20mg, and 40mg per ml, and those of the polyethylene glycol #2000 of (17) were adjusted to 0mg, 1mg, 10mg, and 20mg per ml respectively.

50

55

The results are shown in Table 15. As will be apparent from Table 15, it is confirmed that the polyethylene glycol #2000 augments the antimicrobial activity of the lactoferrin hydrolysate 2. On the other hand, in the case wherein the lactoferrin hydrolysate 2 was not added, but the polyethylene glycol #2000 was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the lactoferrin hydrolysate 2 and the polyethylene glycol #2000. In addition, similar assays were made substituting the lactoferrin hydrolysate 2

with antimicrobial peptides, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of the polyethylene glycol #2000.

Table 15

5

10

15

concentration of polyethylene glycol #2000 (mg/ml)	survival rate			
	concentration of lactoferrin hydrolysate (mg/ml)			
	0	10	20	40
0	100	42	28	11
1	69	39	20	9.4
10	69	34	54	5.5
20	62	8.1	2.3	0.4

Test 16

20

Viability assay was made in such a manner that the eventual concentrations of the lactoferrin hydrolysate 1 of (1)-① in Preparation of Samples (supra) were adjusted to 0mg, 10mg, 20mg, and 40mg per ml, and those of cholic acid of (19) (supra) were adjusted to 0mg, 1mg, 10mg and 20mg per ml respectively.

25

The results are shown in Table 16. As will be apparent from Table 16, it is confirmed that cholic acid augments the antimicrobial activity of the lactoferrin hydrolysate 1. On the other hand, in case wherein the lactoferrin hydrolysate 1 was not added, but cholic acid was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of the antimicrobial activity is resulted from potentiation due to coexistence of the lactoferrine hydrolysate and the cholic acid. In addition, similar assays were made, substituting lactoferrin hydrolysate with antimicrobial peptides, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of cholic acid.

30

45

Table 16

35

40

concentration of cholic acid (mg/ml)	survival rate			
	concentration of lactoferrin hydrolysate (mg/ml)			
	0	10	20	40
0	100	13	1.0	0.8
1	100	8.1	0.4	0.2
10	17	0.9	0.03	0.01
20	18	0.8	0.03	0.006

Test 17

50

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide (Sequence No. 26) of (2)-① (in Preparation of Samples, supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg per ml, and those of 1-monolauroyl-rac-glycerol of (18) (supra) were adjusted to 0mg, 0.5mg, 1mg, and 2mg per ml respectively.

55

The results are shown in Table 17. As will be apparent from Table 17, it is confirmed that 1-monolauroyl-rac-glycerol augments the antimicrobial activity of the antimicrobial peptide. On the other hand, in case wherein the antimicrobial peptide was not added, but 1-monolauroyl-rac-glycerol was added, almost no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the 1-monolauroyl-rac-glycerol. In addition, similar assays were made, substituting antimicrobial peptide was substituted with

lactoferrin hydrolysate, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of 1-monolauroyl-rac-glycerol.

Table 17

5

10

15

concentration of 1-monolauroyl-rac-glycerol (mg/ml)	survival rate			
	concentration of lactoferrin hydrolysate (mg/ml)			
	0	0.5	1	2
0	100	102	92	41
0.5	104	94	77	25
1	88	73	46	12
2	50	20	2.3	0.8

Test 18

20

Viability assay was made with adjusting the eventual concentrations of antimicrobial peptide of (2)-① - (in Preparation of Samples, supra) to 0mg, 0.5mg, 1mg, and 2mg per ml, and those of 1-monomyristoyl-rac-glycerol of (18) (supra) to 0mg, 0.5mg, 1mg and 2mg per ml respectively.

25

The results are shown in Table 18. As will be apparent from Table 18, it is confirmed that the presence of the 1-monomyristoyl-rac-glycerol augmented the antimicrobial activity of the peptide. On the other hand, in the case wherein the antimicrobial peptide was not added, but 1-monomyristoyl-rac-glycerol was added, the antimicrobial activity is low. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the 1-monomyristoyl-rac-glycerol. In addition, similar assays were made, substituting the antimicrobial peptides with lactoferrin hydrolysate, thereby it is confirmed that antimicrobial activity was potentiated by the coexistence of 1-monomyristoyl-rac-glycerol.

30

Table 18

35

40

45

concentration of 1-monomyristoyl-rac-glycerol (mg/ml)	survival rate			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	85	56	23
0.5	129	41	11	5.3
1	93	13	3.1	1.2
2	7	0.3	0.04	0.005

Test 19

50

Viability assay was made in such a manner that the eventual concentrations in serial dilution of the antimicrobial peptide of (2)-① (in Preparation of Samples) were adjusted to 0mg, 0.5mg, 1mg, and 2mg per ml, and those of the 1-monostearoyl-rac-glycerol of (18) (supra) were adjusted to 0mg, 0.5mg, 1mg and 2mg per ml respectively.

55

The results are shown in Table 19. As will be apparent from Table 19, it is confirmed that the 1-monostearoyl-rac-glycerol augments the antimicrobial activity of the antimicrobial peptide. On the other hand, in the case wherein the antimicrobial peptide was not added, but 1-monostearoyl-rac-glycerol was added, no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide and the 1-monostearoyl-rac-glycerol. In addition, similar assays were made, substituting antimicrobial peptide with

lactoferrin hydrolysate, thereby it is confirmed that the antimicrobial activity was potentiated by the coexistence of 1-monostearoyl rac-glycerol.

Table 19

5

10

15

concentration of 1-monostearoyl-rac-glycerol (mg/ml)	survival rate (%)			
	concentration of antimicrobial peptide (mg/ml)			
	0	0.5	1	2
0	100	69	43	21
0.5	116	74	53	18
1	133	48	19	5.5
2	98	25	5.3	1.7

Test 20

20

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide of (2)-② (in Preparation of Samples, supra) were adjusted to 0mg and 1mg per ml, those of 1-monolauroyl-rac-glycerol of (18) (supra) were adjusted to 0mg and 0.5mg per ml, those of the bovine lactoferrin of (3) (supra) were adjusted to 0mg, and 1mg per ml respectively.

25

The results are shown in Table 20. As will be apparent from Table 20, it is confirmed that the presence of 1-monolauroyl-rac-glycerol and bovine lactoferrin further augments the antimicrobial activity of the antimicrobial peptides. Furthermore, additional tests were made, substituting the antimicrobial peptide specified above with lactoferrin hydrolysate, thereby it is confirmed that antimicrobial activity was potentiated.

30

Table 20

35

40

antimicrobial peptide (mg/ml)	1-monolauroyl rac-glycerol (mg/ml)	bovine lactoferrin (mg/ml)	survival rate (%)
0	0	0	100
1	0	0	76
0	0.5	0	87
0	0	1	105
1	0.5	0	2.1
1	0	1	63
0	0.5	1	66
1	0.5	1	0.06

45

Test 21

50

55

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide of (2)-① (in Preparation of samples, supra) were adjusted to 0mg and 1mg per ml, and those of 1-monolauroyl-rac-glycerol of (18) (supra) were adjusted to 0mg and 0.5mg, and those of chitosan of (15) (supra) were adjusted to 0mg and 0.01mg per ml respectively.

60

The results are shown in Table 21. As will be apparent from Table 21, it is confirmed that the coexistence of 1-monolauroyl-rac-glycerol and chitosan further augments the antimicrobial activity of the peptide. On the other hand, similar assays were made, substituting the antimicrobial peptide with lactoferrin hydrolysate, thereby it is confirmed that antimicrobial activity was potentiated.

Table 21

	antimicrobial peptide (mg/ml)	1-monolauroyl rac-glycerol (mg/ml)	chitosan (mg/ml)	survival rate (%)
5	0	0	0	100
	1	0	0	97
	0	0.5	0	86
	0	0	0.01	73
	1	0.5	0	4.6
	1	0	0.01	1.4
	0	0.5	0.01	41
	1	0.5	0.01	0.02

15

Test 22

Viability assay was made in such a manner that the eventual concentrations of the antimicrobial peptide of (2)-① (in Preparation of Samples, supra) were adjusted to 0mg and 1mg per ml, those of the 1-monolauroyl-rac-glycerol of (18) (supra) were adjusted to 0mg and 0.5mg per ml, and those of the cholic acid of (19) were adjusted to 0mg and 1mg per ml respectively.

The results are shown in Table 22. As will be apparent from Table 22, it is confirmed that the coexistence of the 1-monolauroyl-rac-glycerol and the cholic acid further augments the antimicrobial activity of the peptide. Moreover, similar assays were made, substituting the antimicrobial peptide with lactoferrin hydrolysate, thereby it is confirmed that antimicrobial activity was potentiated.

Table 22

	antimicrobial peptide (mg/ml)	1-monolauroyl rac-glycerol (mg/ml)	cholic acid (mg/ml)	survival rate (%)
30	0	0	0	100
	1	0	0	72
	0	0.5	0	58
	0	0	1	92
	1	0.5	0	0.2
	1	0	1	30
	0	0.5	1	0.6
	1	0.5	1	0.03

40

(II) TEST FOR ANTIMICROBIAL AGENTS CONTAINING LACTOFERRIN HYDROLYSATES AND/OR ANTIMICROBIAL PEPTIDES DERIVED FROM LACTOFERRINS, AND ANTIBIOTICS OR ALTERNATIVELY 45 ANTIBIOTICS AND SPECIFIC COMPOUNDS AS THE EFFECTIVE INGREDIENTS

Firstly, preparation of samples and methods which are commonly used in the tests described hereunder will be described.

50 1. Preparation of Samples

(1) Lactoferrin hydrolysates (Powder)

The product prepared in accordance with the method stated in Example 1 was used.

55 (2) Antimicrobial Peptide (Powder)

The product prepared in accordance with the method stated in Example 4 was used.

(3) Antibiotics

The antibiotics (commercial products) listed in Tables 23 and 27 were used.

5 (4) Lactoferrin

A commercial product of bovine lactoferrin (by Sigma Company) was used.

10 (5) Lysozyme

A commercial product of egg white lysozyme (by Seikagaku Kohgyoh Company) was used.

15 (6) 1-monocaproyl-rac-glycerol

A commercial product of 1-monocaproyl-rac-glycerol (by Sigma Company) was used.

2. Method

(1) Preparation of Precultures of Test Microorganisms

20 Precultures of test microorganisms to be used in the tests described hereunder were prepared in such a manner that; from the frozen preservation of dispersions of test microorganisms, a loop of the respective strains of the microorganisms were taken out and spread onto TRI PETIT CASE SOYA AGAR MEDIA (by BBL Company), and incubated at 37 °C for 16 hours; the colonies grown on the culture media were scraped by a platinum loop and cultivated in 2.1% Mueller-Hinton Broth (by Difco Company) respectively for several hours at 37 °C. The resultant microbial cultures at logarithmic phase in 3×10^6 /ml of microbial concentration were used as the precultures.

(2) Preparation of Test Media

30 The test media to be used in the respective tests were prepared in such a manner that; aqueous solutions in a predetermined concentration of the lactoferrin hydrolysates or the lactoferrin-derived antimicrobial peptides of (1) and (2) in Preparation of Samples (supra), as well as the samples of antibiotics of (3) (supra) were respectively sterilized with filters (by Advantec Company); then a quantity of the resultant 35 solutions of respective samples were selectively added to a quantity of basal medium (Mueller-Hinton Broth) prepared in the eventual concentration of 2.1%, thereby combinations of the samples and their concentrations in the respective test media were adjusted as specified in the respective tests.

(3) Test for Antimicrobial Activity

40 Antimicrobial activity was examined as follows: A quantity of the respective precultures prepared in (1) immediately above was diluted with 2.1% Mueller-Hinton Broth to result in 2×10^6 /ml of microbial concentration; 100 µl aliquots of the resultant liquid were added to 100 µl aliquots of one of the test media as specified in the respective test; the resultant media were incubated at 37 °C for 16 hours; then the 45 turbidity of the resultant culture broths were measured thereby antimicrobial activity was examined.

(4) Viability Assay

50 Survival rate was examined in such a manner that: 20 µl aliquots of the respective precultures prepared in (1) immediately above were added to 2ml aliquots of the respective test media prepared in paragraph (2) immediately above; the resultant media were incubated at 37 °C for an hour; 200 µl aliquots of the respective resultant culture broths were serially diluted in 10^o with a 1% aqueous solution of peptone; 110 µl aliquots of the resultant diluted solutions were spread onto broth agar plates; after incubation at 37 °C for 24 hours the number of colonys (test colony count) grown on the plates were counted. On the other 55 hand control colony count was enumerated in the same manner as in the enumeration of test colony count except that 20 µl aliquots of the respective precultures were added to 21 aliquots of 2.1% Mueller-Hinton broth; then survival rate was calculated in accordance with following formula:

Survival Rate = (test colony count/control colony count) × 100

Test 23

5 Components in the test and control media and eventual concentrations thereof were adjusted by properly combining 0mg, 0.4mg, 1.6mg and 6.4mg/ml of lactoferrin hydrolysate of (1) (in Preparation of Samples, supra) or 0 μ g, 16 μ g, 64 μ g, and 256 μ g/ml of lactoferrin-derived antimicrobial peptides of (2) (in Preparation of Samples, supra), and 0 μ g, 0.01 μ g, 0.1 μ g, 1 μ g, and 10 μ g/ml of antibiotics of (3) (supra), then antimicrobial activity of the combined use of the components against Escherichia coli O-111 and
10 Staphylococcus aureus (JCM2151) as well as growth inhibiting concentrations of the antibiotics were investigated.

The results are shown in Tables 23-26. As will be apparent from the tables, it was confirmed that the lactoferrin hydrolysates as well as the antimicrobial peptides potentiated the antimicrobial activity of the antibiotics. On the other hand, no antimicrobial activity was observed when no antibiotics were included, but
15 either one of the lactoferrin hydrolysates or the antimicrobial peptides was included. Therefore, it is apparent that the augmentation of antimicrobial activity was resulted from potentiation due to coexistence of lactoferrin hydrolysates or antimicrobial peptides.

In addition, similar assay was made, utilizing antimicrobial peptides other than that used in this test, it is confirmed that the antimicrobial activity of the antibiotics was potentiated by the coexistence thereof.

20

Table 23

Test Microorganism: Escherichia coli O-111					
25	antibiotics	Growth inhibiting Concentration of antibiotics (μ g/ml)			
		concentrations of lactoferrin hydrolysate (mg/ml)			
		0	0.4	1.6	6.4
30	penicillin	>1	1	1	0.1
	ampicillin	>1	1	1	0.01
	cephalothin	>1	>1	1	0.01
	erythromycin	>1	1	1	0.1
	kanamycin	>1	>1	1	0.1
	staphcillin	>1	>1	>1	0.1
	streptomycin	>1	>1	1	0.01
	hostacyclin	1	1	1	0.1
	gentamicin	1	1	0.1	0.1
	polymyxin B	>1	>1	0.1	0.01
40	chloramphenicol	>1	>1	>1	0.1

45

50

55

Table 24

Test Microorganism: <i>Staphylococcus aureus</i> JCM2151				
antibiotics	Growth inhibiting Concentration of antibiotics ($\mu\text{g/ml}$)			
	concentrations of lactoferrin hydrolysate (mg/ml)			
	0	0.4	1.6	6.4
penicillin	>1	1	1	0.1
ampicillin	>1	1	1	0.1
cephalothin	>1	1	1	0.01
erythromycin	>1	1	1	0.01
kanamycin	>1	>1	>1	0.1
staphcillin	>1	>1	>1	0.1
streptomycin	>1	>1	1	0.1
hostacyclin	1	1	1	0.1
gentamicin	1	0.1	0.1	0.1
polymyxin B	>1	0.1	0.1	0.1
chloramphenicol	>1	>1	>1	1

Table 25

Test Microorganism: <i>Escherichia coli</i> 0-111				
antibiotics	Growth inhibiting Concentration of antibiotics ($\mu\text{g/ml}$)			
	concentrations of antimicrobial peptide (mg/ml)			
	0	16	64	256
penicillin	>1	>1	1	0.1
ampicillin	>1	1	1	0.1
cephalothin	>1	>1	1	0.01
erythromycin	>1	1	1	0.01
kanamycin	>1	>1	1	0.01
staphcillin	>1	>1	1	0.01
streptomycin	>1	>1	1	0.01
hostacyclin	1	1	1	0.1
gentamicin	1	1	0.1	0.1
polymyxin B	>1	>1	0.1	0.1
chloramphenicol	>1	>1	1	0.1

45

50

55

Table 26

		Test Microorganism: Staphylococcus aureus JCM2151			
antibiotics		Growth inhibiting Concentration of antibiotics ($\mu\text{g/ml}$)			
		concentrations of antimicrobial peptides (mg/ml)			
		0	16	64	256
10	penicillin	>1	1	1	0.1
	ampicillin	>1	1	1	0.1
	cephalothin	>1	1	1	0.01
	erythromycin	>1	1	1	0.01
	kanamycin	>1	>1	1	0.01
	staphcillin	>1	>1	1	0.01
	streptomycin	>1	>1	1	0.01
	hostacyclin	1	1	1	0.1
	gentamicin	1	0.1	0.1	0.1
	polymyxin B	>1	0.1	0.1	0.1
20	chloramphenicol	>1	>1	1	1

Test 24

25 Components in the test and control media and eventual concentrations thereof were adjusted by properly combining 0 μg , 10 μg , 100 μg and 1000 $\mu\text{g/ml}$ of lactoferrin-derived antimicrobial peptides of (2) (in Preparation of Samples, supra), and 0 μg , 10 μg , and 50 $\mu\text{g/ml}$ of antibiotics of (3) (supra), then viability assay was made on an antibiotics-resistant microorganisms (methicillin-resistant Staphylococcus aureus (wild type)).

30 The results are shown in Tables 27. As will be apparent from table 27, it was confirmed that the antimicrobial peptides potentiated the antimicrobial activity of the antibiotics. On the other hand, no antimicrobial activity was observed when antibiotics were not included, but antimicrobial peptides were added. Therefore, it is apparent that the augmentation of the antimicrobial activity was resulted from potentiation due to coexistence of the antimicrobial peptides.

35 In addition, similar assay was made, utilizing antimicrobial peptides other than that used in this test, it is confirmed that the antimicrobial activity of the antibiotics was potentiated by the coexistence thereof.

Table 27

40	concentration of minomycin ($\mu\text{g/ml}$)	survival rate (%)			
		concentrations of antimicrobial peptide ($\mu\text{g/ml}$)			
		0	10	100	1000
45	0	100	69	60	3.6
	10	32	21	21	0.01
	50	5.2	4.8	2.4	<0.002

50

Test 25

Components in the test and control media and eventual concentrations thereof were adjusted by properly combining 0 μg and 10 $\mu\text{g/ml}$ of lactoferrin-derived antimicrobial peptides of (2) (in Preparation of Samples, supra), and 10 μg and 100 $\mu\text{g/ml}$ of lactoferrin of (4) (in Preparation of Samples, supra), lysozyme of (5) (supra) or 1-monocapryloyl rac-glycerol of (6) (supra), and 0 μg and 1 $\mu\text{g/ml}$ of antibiotics of (3) (supra), then viability assay was made on Staphylococcus aureus (JCM-2151).

The results are shown in Tables 28. As will be apparent from the table, the coexistence of the antimicrobial peptide, and either one of lactoferrin, lysozyme, and 1-monocapryloyl-rac-glycerol augments the antimicrobial activity of the antibiotics. On the other hand, when the antimicrobial peptide, and either one of the lactoferrin, lysozyme, and 1-monocapryloyl-rac-glycerol were added, but antibiotics was not added, almost no antimicrobial activity was observed. Therefore, it is apparent that the augmentation of the antimicrobial activity is resulted from potentiation due to coexistence of the antimicrobial peptide, and either one of lactoferrin, lysozyme, and 1-monocapryloyl-rac-glycerol as well as the antibiotics.

In addition, similar assay was made utilizing antimicrobial peptides other than that used in this test, or lactoferrin hydrolysates, metal-chelating proteins, decomposed casein, tocopherol, cyclodextrin, glycerine-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cystein, or cholic acid and an antibiotics other than that used in this test, it is confirmed that the antimicrobial activity of the antibiotics was potentiated.

Table 28

15

20

25

30

		survival rate (%)		
		control	penicillin (1μg/ml)	streptomycin (1μg/ml)
	control	100	14.2	12.4
	antimicrobial peptide (10μg/ml)	60	0.4	0.2
	antimicrobial peptide (10μg/ml) + lactoferrin (100μg/ml)	7.4	<0.01	<0.01
	antimicrobial peptide (10μg/ml) + lysozyme (100μg/ml)	6.5	<0.01	<0.01
	antimicrobial peptide (10μg/ml) + 1 monocapryloyl-rac-glycerol (100μg/ml)	7.3	<0.01	<0.01

AS explained in detail in the foregoing tests, it will be understood that the present invention provides antimicrobial agents which have excellent antimicrobial activity against a wide variety of microorganisms, and which can be safely used for foods, drugs and the like. Since the antimicrobial agents of this invention exhibit potentiated antimicrobial activity with a minor quantity, almost no affect on the palatability of the foods when they are used for treatment thereof.

Moreover, when an antibiotic is included as one of the effective components of the antimicrobial agent, the antimicrobial activity of the antibiotic is remarkably potentiated, thus it is possible to reduce the quantity of the antibiotic to be included therein. In addition, the antimicrobial agents of this invention exhibit remarkable antimicrobial activity against microorganisms which have tolerance to a certain kinds of antibiotics.

Now, Some examples will be described hereunder more concretely and more precisely for explanation of the present invention, however, it should be noted that the present invention is not limited thereto.

45 Example 1

About 1000g of a solution of lactoferrin hydrolysate was yielded in such a manner that: 50g or commercial lactoferrin just as isolated from cow's milk was dissolved into 950g of distilled water; the resultant solution was heated at 120 °C for 15 minutes; after the pH of the resultant solution was adjusted to 2 with 1N hydrochloric acid; then the resultant solution of lactoferrin hydrolysate was cooled (concentration of the lactoferrin hydrolysate: 5%). The hydrolyzing rate of the product was 9%.

From the solution of lactoferrin hydrolysate, about 49g of powdery lactoferrin hydrolysate was yielded by concentrating the solution under diminished pressure, followed by freezedrying. An antimicrobial agent of this invention was prepared by homogeneously mixing 10g of the powdered lactoferrin hydrolysate and 1g of EDTA • 2 sodium (by Wako Junyaku Company).

Example 2

5 About 10kg of a solution of lactoferrin hydrolysate (concentration of the products: 10%) was yielded in such a manner that 1kg of commercial lactoferrin (by Orefina company, Belgium) just as isolated from cow's milk was dissolved into 9kg of distilled water, followed by adjustment of pH to 2.5 by addition of 2 mole citric acid, addition of 30g of commercial swine pepsin (1:10000; by Wakoh Junyaku Company) to the resultant liquid, incubation of the resultant liquid at 37°C for 180 minutes, deactivation of the pepsin by heating at 80°C for 10 minutes, and cooling the resultant solution. The hydrolyzing rate of the product was 11.3%.

10 From the solution of lactoferrin hydrolysate, about 960g of powdery lactoferrin hydrolysate was yielded by concentrating the solution under diminished pressure, followed by freezedrying. An antimicrobial agent of this invention was prepared by homogeneously mixing 100g of the powdered lactoferrin hydrolysate and 30g of citric acid (by Nakarai tesk Company).

15 Example 3

Hydrolysis of lactoferrin was made in such a manner that: 50mg of commercial bovine lactoferrin (by Sigma Company) was dissolved into 0.9ml of distilled water; pH of the resultant solution was adjusted to 2.5 by addition of 0.1N hydrochloric acid; after adding 1mg of commercial swine pepsin (by Sigma Company) the resultant solution was hydrolyzed at 37°C for 6 hours; the pH of the resultant solution was adjusted to 7.0 with 0.1N sodium hydroxide; then the enzyme was deactivated by heating at 80°C for 10 minutes; the resultant liquid was cooled and centrifuged at 15,000rpm for 30 minutes thereby a clear supernatant containing lactoferrin hydrolyzate was obtained.

One hundred (100) µl of the supernatant was passed through a column of TSK gel ODS 120T (by TOHSOH Company) at a flow rate of 0.8ml/min., then the column was rinsed with 20% acetonitrile containing 0.05% of TFA (trifluoro acetate) for 10 minutes. Acetonitrile gradient (20-60%) containing 0.05% of TFA was further passed through the column for 30 minutes during which period a fraction eluted between 24-25 minutes was collected and dried under diminished pressure.

The resultant powder (lactoferrin hydrolysate) was dissolved into distilled water to make a 2% (w/v) solution which was passed through a column of TSK gel ODS-120T (by TOHSOH Company) at a flow rate of 0.8ml/min. Acetonitrile (24%) containing 0.05% TFA was passed through the column for 10 minutes, then 24-32% acetonitrile gradient containing 0.05% of TFA was passed through the column for 30 minutes during which a fraction eluted between 33.5-35.5 minutes was collected. The latter HPLC procedure was repeated 25 times, the resultant eluate was dried under diminished pressure to thereby obtain 1.5mg of antimicrobial peptide.

The resultant antimicrobial peptide was hydrolyzed with 6N hydrochloric acid, then amino acid composition thereof was analyzed with an amino acid analyzer in accordance with the conventional method. The same sample was subjected to vapor phase sequencer (by Applied Bio=Systems Company) to make Edman decomposition 25 times thereby the sequence of 25 amino acid residues was determined. Also, presence of disulfide linkage in the peptide was confirmed by the disulfide-linkage analysis (Analytical Biochemistry; Vol. 67, page 493, 1975) utilizing DTNB (5,5-dithio-bis(2-nitrobenzoic acid)).

As a result, it is confirmed that this peptide have an amino acid sequence as shown in Sequence No. 26 (infra), consisting of 25 amino acid residues, and having a disulfide linkage between 3rd and 20th cysteine residues, and that two amino acid residues bonded to the 3rd cysteine residue on the N terminus side, and 5 amino acid residues bonded to the 20th cysteine residue on the C-terminus side.

An antimicrobial preparation of this invention was prepared by homogeneously mixing 1g of commercial lactoferrin (by Sigma Company) to 100mg of the powdery antimicrobial peptide.

Example 4

50 An antimicrobial peptide of which amino acid sequence is known (Sequence No. 27) was synthesized with peptide-auto-synthesizer (LKB Bionyx 4170, by Pharmacia LKB Biotechnology Company) in accordance with Solid Phase Peptide Synthesis by Shepperd et al. (Journal of Chemical Society Perkin I, page 533, 1981), the particulars of which are as follows:

55 Anhydrides of desired amino acids were produced by adding N,N-dicyclohexylcarbodiimide to said amino acids of which amine-functional groups were previously protected with 9-fluorenyl methoxy carbonyl groups. The resultant Fmoc-amino acid anhydrides were used for synthesis of the peptide. Peptide chains in a known amino acid sequence were formed in such a manner that Fmoc-lysine anhydrides which

correspond to the lysine residue at the C-terminus of the peptide was fixed to Ultrasyn A resin (by Pharmacia LKB Biotechnology Company) with their carboxyl groups under the presence of dimethylaminopyridine as a catalyst. Washing the resin with dimethylformamide containing pyridine to thereby remove the protective groups bonded to amine-functional groups of the C-terminus amino acids (lysine); the Fmoc-lysine anhydrides which correspond to 2nd amino acid from the C-terminus in the amino acid sequence were coupled to the deprotected amine-functional groups of the C-terminal lysine which was previously fixed to the resin. In the same manner, methionine, arginine, tryptophan, glutamine, tryptophan, arginine, arginine, threonine, and lysine were successively coupled to the amino acid which was coupled immediately before. When the successive coupling of all amino acids was completed, and the aimed peptide chains having the desired sequence were formed, removal of the protective groups other than acetamide-methyl and detachment of the synthesized peptides from the resin were performed by addition of a solvent consisting of 94% TFA, 5% of phenol, and 1% of ethandiol, the resultant solution of the peptide was purified with HPLC, then the purified solution was concentrated and dried to thereby obtain the peptide powder.

The amino acid composition of the resultant peptide was analyzed with an amino acid analyzer in accordance with the conventional method, thereby it is confirmed that the synthesized peptides have the amino acid sequence as shown in Sequence No. 27.

An antimicrobial agent of this invention was prepared by homogeneously mixing 100mg of the synthesized antimicrobial peptide with 2g of caseinphosphopeptide (the same one used in Test 2, supra).

20 Example 5

An antimicrobial agent of this invention was prepared by homogeneously mixing 40g of the powdered lactoferrin hydrolysate prepared in the same method as in Example 1 and 2mg of streptomycin.

25 Example 6

An antimicrobial agent of this invention was prepared by homogeneously mixing 100g of the powdered lactoferrin hydrolysate prepared in the same method as in Example 2 and 1mg of polymyxin B.

30 Example 7

An antimicrobial agent of this invention was prepared by homogeneously mixing 500g of the powdered lactoferrin hydrolysate prepared in the same method as in Example 2 and 0.1g of oxtetracyclin.

35 Example 8

An antimicrobial agent of this invention was prepared by homogeneously mixing 100mg of the antimicrobial peptide prepared in the same method as in Example 3 and 1mg of minocycline (tetracycline antibiotics).

Example 9

An antimicrobial agent of this invention was prepared by homogeneously mixing 100mg of the antimicrobial peptide prepared in the same method as in Example 3 and 1mg of penicillin G.

Example 10

An antimicrobial agent of this invention was prepared by homogeneously mixing 10mg of the antimicrobial peptide prepared in the same method as in Example 3, 100mg of lysozyme, and 1mg of penicillin G.

Example 11

An antimicrobial agent of this invention was prepared by homogeneously mixing 100mg of the antimicrobial peptide prepared in the same method as in Example 4 and 0.5mg of gentamicin.

Example 12

Eye lotion (aqueous solution) was prepared with the following ingredients in accordance with the conventional method.

5

boric acid	1.60 (%)
antimicrobial agent of Example 4	0.15
methyl cellulose	0.50

10

Example 13

Chewing gum was prepared with the following ingredients in accordance with the conventional method.

15

gum base	25.00 (%)
calcium carbonate	2.00
perfumery	1.00
antimicrobial agent of Example 2	0.02
sorbitol powder	71.89

20

Example 14

25

Tooth paste was prepared with the following ingredients in accordance with the conventional method.

30

calcium secondary phosphate • 2 hydrate	36.93 (%)
sorbitol	45.00
glycerin	15.00
carboxymethyl cellulose • sodium	1.50
sorbitan fatty acid ester	0.50
saccharin sodium	1.00
antimicrobial agent of Example 1	0.07

35

Example 15

40 Skin cleanser (rinse) was prepared with the following ingredients in accordance with the conventional method. In use, the skin cleanser is diluted 50-fold with water.

45

sodium chloride	8.0 (%)
antimicrobial agent of Example 3	0.8
distilled water	91.2

Example 16

50

A composition affecting epidermis (ointment) was prepared with the following ingredients in accordance with the conventional method.

55

5	ethyl p-hydroxybenzoate	0.10 (%)
	butyl p-hydroxybenzoate	0.10
	lauromacrogol	0.50
	cetanol	18.00
	white petrolatum	40.00
	distilled water	40.85
	peptide of Sequence No. 27	0.15
	1-monomyristoyl-rac-glycerol	0.30

10

Example 17

Hand lotion was prepared with the following ingredients in accordance with the conventional method.

15

20	carbowax 1500	8.00 (%)
	alcohol	5.00
	propylene glycol	52.00
	distilled water	33.90
	perfumery	0.30
	peptide of Sequence No. 26	0.20
	1-monolauroyl rac glycerol	0.20
	cholic acid	0.40

25

Example 18

Eye lotion (aqueous solution) was prepared with the following ingredients in accordance with the conventional method.

35

boric acid	1.60 (%)
antimicrobial agent of Example 5	0.15
methyl cellulose	0.50

Example 19

40 A composition affecting epidermis was prepared with the following ingredients in accordance with the conventional method.

45

45	ethyl p-hydroxybenzoate	0.1 (%)
	butyl p-hydroxybenzoate	0.1
	lauromacrogol	0.5
	cetanol	20.0
	white petrolatum	40.0
	water	29.3
	antimicrobial agent of Example 6	10.0

50

Example 20

55 Feed for animals was prepared with the following ingredients in accordance with the conventional method.

5

dried fish powder	30.0 (%)
soybean grounds	39.9
wheat	30.0
antimicrobial agent of Example 7	0.1

Example 21

10 A composition affecting epidermis was prepared with the following ingredients in accordance with the conventional method.

15

20

ethyl p-hydroxybenzoate	0.1 (%)
butyl p-hydroxybenzoate	0.1
lauromacrogol	0.5
cetanol	20.0
white petrolatum	40.0
water	29.3
antimicrobial agent of Example 8	10.0

Example 22

25 A therapeutic composition for mammitis was prepared with the following ingredients in accordance with the conventional method.

30

1,2-hydroxystearin	0.1 (%)
glyceromonostearate	0.5
butylated hydroxyanisol	0.02
peanut oil	93.48
antimicrobial agent of Example 9	5.0

35

Example 23

A composition affecting epidermis was prepared with the following ingredients in accordance with the conventional method.

40

45

ethyl p-hydroxybenzoate	0.1 (%)
butyl p-hydroxybenzoate	0.1 (%)
lauromacrogol	0.5
cetanol	20.0
white petrolatum	40.0
water	29.3
antimicrobial agent of Example 10	10.0

50

Example 24

Antibiotic agent having following composition was prepared in accordance with the conventional method.

55

Antimicrobial agent of Example 11	100.0 (%)
-----------------------------------	-----------

INDUSTRIAL APPLICATION

The antimicrobial agent of this invention is useful as drugs having potent antimicrobial activity against bacteria, yeasts, fungi, and the like. Especially, it is useful for prevention and treatment of microbial infection caused by microorganisms which is resistive to wide variety of antibiotics. It is also useful for treatment of various matters such as drugs, foods, and the like with safety and great efficiency.

SEQUENCE LISTING

10 Sequence Number: 1
Length : 11

15

20

25

30

35

40

45

50

55

5 type : amino acid
topology: linear
species : peptide
feature : the specified peptide as well as peptides including the
 specified peptide as a fragment thereof
sequence:

10 Lys Xaa Xaa Xaa Xaa Gln Xaa Xaa Met Lys Lys
 1 5 10

(In the sequence indicated above, Xaa denotes an optional amino acid
residue except Cys.)

15 Sequence Number: 2
length : 11
type : amino acid
20 topology: linear
species : peptide
feature : the specified peptide as well as peptides including the
 specified peptide as a fragment thereof
25 sequence:
Lys Xaa Xaa Xaa Xaa Gln Xaa Xaa Met Arg Lys
 1 5 10

30 (In the sequence indicated above, Xaa denotes an optional amino acid
residue except Cys.)

Sequence Number: 3
35 length : 6
type : amino acid
topology: linear
species : peptide
40 feature : the specified peptide as well as peptides including the
 specified peptide as a fragment thereof
sequence:
Arg Xaa Xaa Xaa Xaa Arg
45 1 5

(In the sequence indicated above, Xaa denotes an optional amino acid
residue except Cys.)

50

55

Sequence Number: 4

length : 6
5 type : amino acid
topology: linear
species : peptide
feature : the specified peptide as well as peptides including the
10 specified peptide as a fragment thereof
sequence:

Lys Xaa Xaa Xaa Xaa Arg

1 5

15 (In the sequence indicated above, Xaa denotes an optional amino acid residue except Cys.)

Sequence Number: 5

20 length : 6
type : amino acid
topology: linear
25 species : peptide
feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof
sequence:

Lys Xaa Xaa Xaa Xaa Lys

30 1 5

(In the sequence indicated above, Xaa denotes an optional amino acid residue except Cys.)

35 Sequence Number: 6

length : 6
40 type : amino acid
topology: linear
species : peptide
feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof
45 sequence:

Arg Xaa Xaa Xaa Xaa Lys

50

55

1 5
5 (In the sequence indicated above, Xaa denotes an optional amino acid residue except Cys.)

Sequence Number: 7
length : 5
10 type : amino acid
topology: linear
species : peptide
feature : the specified peptide as well as peptides including the
15 specified peptide as a fragment thereof
sequence:
Arg Xaa Xaa Xaa Arg
1 5
20 (In the sequence indicated above, Xaa denotes an optional amino acid residue except Cys.)

25 Sequence Number: 8
length : 5
type : amino acid
topology: linear
30 species : peptide
feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof
sequence:
Lys Xaa Xaa Xaa Arg
1 5
35 (In the sequence indicated above, Xaa denotes an optional amino acid residue except Cys.)

40 Sequence Number: 9
length : 5
45 type : amino acid
topology: linear
species : peptide
feature : the specified peptide as well as peptides including the

50

55

specified peptide as a fragment thereof

sequence:

Arg Xaa Xaa Xaa Lys

1 5

(In the sequence indicated above, Xaa denotes an optional amino acid residue except Cys.)

10 Sequence Number: 10

length : 6

type : amino acid

15 topology: linear

species : peptide

feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

20 sequence:

Phe Gln Trp Gln Arg Asn

1 5

25

Sequence Number: 11

length : 5

type : amino acid

30 topology: linear

species : peptide

feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

35 sequence:

Phe Gln Trp Gln Arg

1 5

40

Sequence Number: 12

length : 4

type : amino acid

45 topology: linear

species : peptide

feature : the specified peptide as well as peptides including the

50

55

specified peptide as a fragment thereof
sequence:

5 Gln Trp Gln Arg

1

Sequence Number: 13

10 length : 3

type : amino acid

topology: linear

species : peptide

15 feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

sequence:

Trp Gln Arg

20 1

Sequence Number: 14

length : 5

25 type : amino acid

topology: linear

species : peptide

30 feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

sequence:

Arg Arg Trp Gln Trp

35 1

5

Sequence Number: 15

length : 4

40 type : amino acid

topology: linear

species : peptide

45 feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

sequence:

Arg Arg Trp Gln

50

55

1

Sequence Number: 16

length : 4

type : amino acid

topology: linear

species : peptide

feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

sequence:

Trp Gln Trp Arg

1

Sequence Number: 17

length : 3

type : amino acid

topology: linear

species : peptide

feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

sequence:

Gln Trp Arg

1

Sequence Number: 18

length : 6

type : amino acid

topology: linear

species : peptide

feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

sequence:

Leu Arg Trp Gln Asn Asp

1

5

Sequence Number: 19

50

55

length : 5
type : amino acid
topology: linear
5 species : peptide
feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof
sequence:
10 Leu Arg Trp Gln Asn
1 5

15 Sequence Number: 20
length : 4
type : amino acid
topology: linear
20 species : peptide
feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof
sequence:
25 Leu Arg Trp Gln
1

30 Sequence Number: 21
length : 3
type : amino acid
topology: linear
35 species : peptide
feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof
sequence:
40 Arg Trp Gln
1

45 Sequence Number: 22
length : 20
type : amino acid
topology: linear

50

55

species : peptide

feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

5 In the sequence indicated hereunder, 2nd and 9th cysteins
are bonded with disulfide linkage.

sequence:

10 Lys Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro
1 5 10 15
Ser Ile Thr Cys Val
20

15

Sequence Number: 23

length : 20

type : amino acid

20 topology: linear

species : peptide

feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

25 In the sequence indicated hereunder, Cys* denotes that the
cysteine is prevented by chemical modification of its thiol
group from making disulfide linkage.

sequence:

30 Lys Cys* Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro
1 5 10 15
Ser Ile Thr Cys* Val
20

35

Sequence Number: 24

length : 20

40 type : amino acid

topology: linear

species : peptide

feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

45 In the sequence indicated hereunder, 2nd and 19th cysteins
are bonded with disulfide linkage.

50

55

sequence:

Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg Gly Pro			
1	5	10	15
5 Pro Val Ser Cys Ile			
	20		

Sequence Number: 25

10 length : 20
 type : amino acid
 topology: linear
 species : peptide
 15 feature : the specified peptide as well as peptides including the
 specified peptide as a fragment thereof
 In the sequence indicated hereunder, Cys* denotes that the
 20 cystein is prevented by chemical modification of its thiol
 group from making disulfide linkage.

sequence:

Lys Cys* Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg Gly Pro			
25 1	5	10	15
Pro Val Ser Cys* Ile			
	20		

30 Sequence Number: 26

length : 25
 type : amino acid
 topology: linear
 35 species : peptide
 feature : the specified peptide as well as peptides including the
 specified peptide as a fragment thereof
 In the sequence indicated hereunder, 3rd and 20th cysteins
 40 are bonded with disulfied linkage.

sequence:

Phe Lys Cys Arg Arg 'frp Gln Trp Arg Met Lys Lys Leu Gly Ala			
45 1	5	10	15
Pro Ser Ile Thr Cys Val Arg Arg Ala Phe			
	20	25	

50

55

Sequence Number: 27

length : 11

5 type : amino acid

topology: linear

species : peptide

feature : the specified peptide as well as peptides including the
10 specified peptide as a fragment thereof

sequence:

Lys Thr Arg Arg Trp Gln Trp Arg Met Lys Lys

1

5

10

15

Sequence Number: 28

length : 38

20 type : amino acid

topology: linear

species : peptide

feature : the specified peptide as well as peptides including the
25 specified peptide as a fragment thereof

In the sequence indicated hereunder, 16th and 33rd cysteins
are bonded with disulfide linkage.

sequence:

Lys Asn Val Arg Trp Cys Thr Ile Ser Gln Pro Glu Trp Phe Lys

30

1

5

10

15

Cys Arg Arg Trp Gln Trp Arg Met Lys Lys Leu Gly Ala Pro Ser

20

25

30

Ile Thr Cys Val Arg Arg Ala Phe

35

Sequence Number: 29

40 length : 32

type : amino acid

topology: linear

species : peptide

45 feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

50

55

In the sequence indicated hereunder, 10th and 27th cysteins
are bonded with disulfide linkage.

Sequence:

5 Thr Ile Ser Gln Pro Glu Trp Phe Lys Cys Arg Arg Trp Gln Trp
 1 5 10 15
 Arg Met Lys Lys Leu Gly Ala Pro Ser Ile Thr Cys Val Arg Arg
 20 25 30
10 Ala Phe

Sequence Number: 30

15 length : 47
type : amino acid
topology: linear
species : peptide
20 feature : the specified peptide as well as peptides including the
 specified peptide as a fragment thereof
 In the sequence indicated hereunder, there are two disulfide
 linkages between 9th and 26th cysteins in the longer
25 peptide chain having 36 amino acids, and 35th cystein of the
 longer peptide chain and 10th cystein of the shorter
 peptide chain having 11 amino acids.

sequence:

30 Val Ser Gln Pro Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn
 1 5 10 15
 Met Arg Lys Val Arg Gly Pro Pro Val Ser Cys Ile Lys Arg Asp
 20 25 30
35 Ser Pro Ile Gln Cys Ile
 35
 Gly Arg Arg Arg Arg Ser Val Gln Trp Cys Ala
 1 5 10
40

Sequence Number: 31

45 length : 5
type : amino acid
topology: straight chain
species : peptide

50

55

feature : the specified peptide as well as peptides including the
specified peptide as a fragment thereof

sequence:

5 Lys Xaa Xaa Xaa Lys

1 5

(In the sequence indicated above, Xaa denotes an optional amino acid residue except Cys.)

10

Claims

- 15 1. An antimicrobial agent containing (A) lactoferrin hydrolysate and/or one or more of antimicrobial peptides derived from lactoferrins, and (B) one or more compounds selected from the group consisting of metal-chelating protein, tocopherol, cyclodextrin, glycerin-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, and cholic acid as the effective components thereof.
- 20 2. The antimicrobial agent of claim 1, wherein said metalchelating protein comprises lactoferrin, transferrin, conalbumin, or casein phosphopeptides.
- 25 3. An antimicrobial agent containing (A) lactoferrin hydrolysate and/or one or more of antimicrobial peptides derived from lactoferrins, and (C) at least an antibiotic as the effective components thereof.
- 30 4. The antimicrobial agent of claim 1, wherein (C) said antibiotic includes penicillin, semi-synthetic penicillin, cephem antibiotic, carbapenem antibiotics, monobactam antibiotics, aminoglycoside antibiotics, peptide antibiotics, tetracycline antibiotics, chloramphenicol, macrolide antibiotics, rifamycin, vancomycin, fosfomycin, synthetic antimicrobial agent, antifungal drug, antituberculosis drug, and polymyxin B.
- 35 5. An antimicrobial agent containing (A) lactoferrin hydrolysate and/or one or more of antimicrobial peptides derived from lactoferrins, (C) at least an antibiotic, and (B) one or more compounds selected from the group consisting of metal-chelating protein, lysozyme, decomposed casein, tocopherol, cyclodextrin, glycerin-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, and cholic acid as the effective components thereof.
- 40 6. The antimicrobial agent of claim 5, wherein said antibiotic includes penicillin, semi synthetic penicillin, cephem antibiotic, carbapenem antibiotics, monobactam antibiotics, aminoglycoside antibiotics, peptide antibiotics, tetracycline antibiotics, chloramphenicol, macrolide antibiotics, rifamycin, vancomycin, fosfomycin, synthetic antimicrobial agent, antifungal drug, antituberculosis drug, and polymyxin B.
- 45 7. The antimicrobial agent of claim 5, wherein said metal-chelating protein comprises lactoferrin, transferrin, conalbumin, or casein phosphopeptides originating from α -casein, or β -casein.
- 50 8. A method for treatment of a matter with an antimicrobial agent containing (A) lactoferrin hydrolysate and/or one or more of antimicrobial peptides derived from lactoferrins, and (B) one or more compounds selected from the group consisting of metal-chelating protein, tocopherol, cyclodextrin, glycerin-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, and cholic acid as the effective components thereof.
- 55 9. The method of Claim 8, wherein said metal-chelating protein comprises lactoferrin, transferrin, conalbumin, or casein phosphopeptides.

10. A method for treatment of a matter with an antimicrobial agent containing (A) one or more of antimicrobial peptides derived from lactoferrins, and (C) at least an antibiotic as the effective components thereof.
- 5 11. The method of Claim 10, wherein said antibiotic comprises penicillin, semi-synthetic penicillin, cephem antibiotic, carbapenem antibiotics, monobactam antibiotics, aminoglycoside antibiotics, peptide antibiotics, tetracycline antibiotics, chloramphenicol, macrolide antibiotics, rifamycin, vancomycin, fosfomycin, synthetic antimicrobial agent, antifungal drug, antituberculosis drug, and polymyxin B.
- 10 12. A method for treatment of a matter with an antimicrobial agent containing (A) lactoferrin hydrolysate and/or one or more of antimicrobial peptides derived from lactoferrins, (C) at least an antibiotic, and (B) one or more compounds selected from the group consisting of metal-chelating protein, lysozyme, decomposed casein, tocopherol, cyclodextrin, glycerin-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, and cholic acid as the effective components thereof.
- 15 13. The method of Claim 12, wherein said antibiotic comprises penicillin, semi-synthetic penicillin, cephem antibiotic, carbapenem antibiotics, monobactam antibiotics, aminoglycoside antibiotics, peptide antibiotics, tetracycline antibiotics, chloramphenicol, macrolide antibiotics, rifamycin, vancomycin, fosfomycin, synthetic antimicrobial agent, antifungal drug, antituberculosis drug, and polymyxin B.
- 20 14. The method of claim 12, wherein said metal-chelating protein comprises lactoferrin, transferrin, conalbumin, or casein phosphopeptides.

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP92/01563

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl ⁵ A01N63/00, A61K37/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Int. Cl ⁵ A01N63/00, A61K37/00		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched.		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP, A, 3-220130 (Snow Brand Milk Products Co., Ltd.), September 27, 1991 (27. 09. 91), (Family: none)	1-14
Y	JP, A, 3-504864 (The Public Health Research Institute of the City of New York, Inc.), October 24, 1991 (24. 10. 91), & WO, A, 9009739 & US, A, 4980163 & EP, A, 424484	1-14
Y	JP, A, 62-129202 (Takeda Chemical Industries, Ltd.), June 11, 1987 (11. 06. 87), & EP, A, 175338	1-14
Y	JP, A, 59-141507 (FBC Ltd.), August 14, 1984 (14. 08. 84), & EP, A, 117600	10-14

<input checked="" type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
<ul style="list-style-type: none"> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 		<ul style="list-style-type: none"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family 	
Date of the actual completion of the international search April 12, 1993 (12. 04. 93)		Date of mailing of the international search report May 11, 1993 (11. 05. 93)	
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP92/01563

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, A, 3-193708 (Bio Cell Laboratoire S.A.), August 23, 1991 (23. 08. 91), & EP, A, 397227 & FR, A, 2646777	1-14
A	JP, A, 2-191205 (Morinaga & Co., Ltd.), July 27, 1990 (27. 07. 90), & EP, A, 389795	1-14